SK Biopharmaceuticals Co., Ltd.
326030
株式のランク
#4039
SK Biopharmaceuticals Co., Ltd. is a pharmaceutical enterprise dedicated to the... SK Biopharmaceuticals Co., Ltd. is a pharmaceutical enterprise dedicated to the research, identification, and development of novel therapies for central nervous system (CNS) disorders. Their product portfolio features Cenobamate, indicated for the treatment of epilepsy, and Solriamfetol, which addresses excessive daytime sleepiness experienced in conditions like narcolepsy or obstructive sleep apnea. The company's robust clinical pipeline includes Carisbamate, currently in Phase 1b/2 trials for Lennox-Gastaut syndrome, and Relenopride, advancing through Phase 2 for a rare neurological disease. Additionally, they have several candidates in Phase 1 development: SKL13865 for attention deficit/hyperactivity disorder (ADHD), SKL20540 for schizophrenia, SKL-PSY for bipolar disorder, and SKL24741, another potential treatment for epilepsy. Founded in 2011, the company is headquartered in Seongnam, South Korea, and functions as a subsidiary of SK Inc.
株価
$51.65
時価総額
$4.05B
変化（1日）
0.27%
変化（1年）
-30.95%
国
KR
取引 SK Biopharmaceuticals Co., Ltd. (326030)
カテゴリー
Healthcare
SK Biopharmaceuticals Co., Ltd.（326030）の利益
Jun 2026 時点の利益 TTM: $199.99M
SK Biopharmaceuticals Co., Ltd. の最新の財務報告によると、同社の現在の利益は $199.99M です。2024 年には $49.38M の利益を上げ、これは 2023 年の利益 $-33.88M と 増加 です。このページに表示されている利益は、利息および税引き前利益、すなわち EBIT です。
SK Biopharmaceuticals Co., Ltd. の利益の推移（2011 〜 2026）
各年末の利益
| 年 | 利益 | 変化 |
|---|---|---|
| 2026 (TTM) | $199.99M | 91.48% |
| 2025 | $104.44M | 111.52% |
| 2024 | $49.38M | -245.75% |
| 2023 | $-33.88M | -69.99% |
| 2022 | $-112.90M | -288.31% |
| 2021 | $59.95M | -127.13% |
| 2020 | $-220.98M | 202.16% |
| 2019 | $-73.13M | -40.83% |
| 2018 | $-123.61M | 36.08% |
| 2017 | $-90.84M | 260.75% |
| 2016 | $-25.18M | 14.75% |
| 2015 | $-21.94M | -33.74% |
| 2014 | $-33.12M | -18.07% |
| 2013 | $-40.42M | 43.63% |
| 2012 | $-28.14M | 57.64% |
| 2011 | $-17.85M | 0.00% |
同業他社の利益
| 企業 | 利益 | 利益の差 | 国 |
|---|---|---|---|
| $5.27B | 2,537.63% |
US
|
|
| $-3.09B | -1,643.61% |
US
|
|
| $-4.02B | -2,108.24% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | 875.39% |
NL
|
